NRF2 Inhibition in Cancer Cell Lines

The cell lines used in this study were: human SKBR3 (breast cancer, carrying R175H p53 mutation), T98MG (glioblastoma, carrying M237I p53 mutation), MCF7 breast cancer, U87 glioblastoma, HCT116 and RKO colon cancer cell lines (all carrying wild-type p53), and HCT116 p53 null. The cells were cultured in either DMEM (Dulbecco modified Eagle’s medium) (Life Technologies-Invitrogen), or RPM1–1640 (Life Technologies-Invitrogen), with 10% heat-inactivated foetal bovine serum (FBS) (Corning, NY, USA, #35–079) and L-glutamine/streptomycin (100 μg/mL) (Corning, NY, USA, #30–002), in 5% CO2 at 37 °C. They were all mycoplasma negative. The NRF2 inhibitor Brusatol [47 (link)] (Sigma-Aldrich) was used at 100 nM, as previously reported [48 (link)].